Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Fuji
US Army
Johnson and Johnson
QuintilesIMS
Merck

Generated: May 24, 2019

DrugPatentWatch Database Preview

AEMCOLO Drug Profile

« Back to Dashboard

Which patents cover Aemcolo, and what generic alternatives are available?

Aemcolo is a drug marketed by Cosmo Technologies and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-five patent family members in eighteen countries.

The generic ingredient in AEMCOLO is rifamycin. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the rifamycin profile page.

Summary for AEMCOLO
International Patents:25
US Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Formulation / Manufacturing:see details
Prior Art and Litigation SupportOrder Prior Art and Litigation support for AEMCOLO
DailyMed Link:AEMCOLO at DailyMed
Drug patent expirations by year for AEMCOLO
Generic Entry Opportunity Date for AEMCOLO
Generic Entry Date for AEMCOLO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, DELAYED RELEASE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for AEMCOLO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cosmo Technologies AEMCOLO rifamycin TABLET, DELAYED RELEASE;ORAL 210910-001 Nov 16, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Cosmo Technologies AEMCOLO rifamycin TABLET, DELAYED RELEASE;ORAL 210910-001 Nov 16, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Cosmo Technologies AEMCOLO rifamycin TABLET, DELAYED RELEASE;ORAL 210910-001 Nov 16, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Farmers Insurance
US Army
Moodys
Accenture
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.